Atea Pharmaceuticals (AVIR)
(Delayed Data from NSDQ)
$3.52 USD
-0.01 (-0.28%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $3.52 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Atea Pharmaceuticals, Inc. has a market cap of $302.10M, which represents its share price of $3.53 multiplied by its outstanding shares number of 85.58M. As a small-cap company, AVIR's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
AVIR 3.52 -0.01(-0.28%)
Will AVIR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AVIR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AVIR
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?
Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates
AVIR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y
VRTX Q3 Earnings & Sales Trump Estimates, '24 Sales View Raised
Transplant Logistic Service Business Likely to Aid TMDX's Q3 Earnings
Other News for AVIR
Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update ...
Atea Pharmaceuticals (AVIR) Launches Phase 3 Trial for Hepatitis C Treatment | AVIR Stock News
Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing ...
Atea Pharmaceuticals announces first patient dosed in Phase 3 C-FORWARD trial
Atea Pharmaceuticals announces first patient dosed in Phase 3 C-FORWARD trial